Tempus AI, Inc. $TEM Holdings Reduced by Level Four Advisory Services LLC

Level Four Advisory Services LLC lessened its holdings in shares of Tempus AI, Inc. (NASDAQ:TEM) by 64.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,677 shares of the company’s stock after selling 10,289 shares during the period. Level Four Advisory Services LLC’s holdings in Tempus AI were worth $458,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Royal Bank of Canada increased its stake in Tempus AI by 201.2% during the 1st quarter. Royal Bank of Canada now owns 25,988 shares of the company’s stock valued at $1,253,000 after buying an additional 17,359 shares during the period. Rhumbline Advisers bought a new stake in Tempus AI in the first quarter worth about $116,000. Envestnet Asset Management Inc. lifted its holdings in Tempus AI by 2.6% in the 2nd quarter. Envestnet Asset Management Inc. now owns 62,005 shares of the company’s stock valued at $3,940,000 after acquiring an additional 1,558 shares during the last quarter. Amalgamated Bank acquired a new stake in Tempus AI in the 2nd quarter valued at about $394,000. Finally, Bank of New York Mellon Corp boosted its position in shares of Tempus AI by 281.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 232,741 shares of the company’s stock valued at $14,788,000 after purchasing an additional 171,776 shares in the last quarter. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on TEM shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tempus AI in a report on Thursday, January 22nd. BTIG Research reduced their target price on shares of Tempus AI from $105.00 to $90.00 and set a “buy” rating for the company in a report on Wednesday, February 25th. Mizuho began coverage on Tempus AI in a report on Thursday, February 19th. They issued an “outperform” rating and a $100.00 price target on the stock. Stifel Nicolaus set a $60.00 price objective on Tempus AI in a research note on Wednesday, February 25th. Finally, Piper Sandler decreased their price target on Tempus AI from $105.00 to $80.00 and set a “neutral” rating for the company in a research report on Tuesday, November 11th. Eight research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $78.15.

Tempus AI Stock Down 1.5%

Tempus AI stock opened at $52.26 on Friday. Tempus AI, Inc. has a twelve month low of $36.22 and a twelve month high of $104.32. The company has a debt-to-equity ratio of 2.52, a quick ratio of 3.00 and a current ratio of 3.13. The firm has a market cap of $9.30 billion, a PE ratio of -37.06 and a beta of 5.29. The firm’s 50 day moving average price is $60.14 and its two-hundred day moving average price is $72.59.

Insider Buying and Selling at Tempus AI

In other Tempus AI news, EVP Andrew Polovin sold 10,949 shares of the business’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $60.31, for a total value of $660,334.19. Following the completion of the sale, the executive vice president directly owned 126,918 shares of the company’s stock, valued at $7,654,424.58. The trade was a 7.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Erik Phelps sold 9,464 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $59.43, for a total transaction of $562,445.52. Following the transaction, the executive vice president owned 79,816 shares in the company, valued at approximately $4,743,464.88. This trade represents a 10.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 590,109 shares of company stock worth $37,056,566 over the last 90 days. 26.27% of the stock is currently owned by insiders.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.